




IMMUNITRACK

TRANSFORMING PRECISION IMMUNOTHERAPIES

New avenues for treating cancer: TCR-LA targeting intracellular tumor antigens



	TCR	TCR-LA
Specificity	Tend to be cross-reactive	Can be engineered to be very specific
Affinity	Micromolar or modified to nanomolar	Nanomolar to picomolar
Plasma kinetics	Soluble forms are unstable. ImmTac half-life is 6-8h	Half-life from hours to weeks based on structure
Therapeutic format	Bispecific forms or transduced into T cells	Native IgG, Bispecific forms, ADC, CAR, radioconjugate
Effector function	Directs or re-directs T cells to kill	Redirects T cells to kill, recruits NK cells or Mac to kill. Vehicle for drug or isotope delivery

High throughput platform for epitope discovery – NeoScreen

Immunitrack has a high throughput platform for epitope discovery by conducting affinity and stability assessments of MHC/epitope complexes (NeoScreen platform). With this technology we have identified immunogenic targets of cancer testis antigens and of cancer driver mutations. We have a large library of MHC Class I and Class II molecules, which allows us to discover antigens that could target the whole population.

Production of highly pure peptide/MHC complexes

Immunitrack can produce best-in-class highly pure peptide/MHC complexes, as a starting material to discover TCR-LAS using any preferred antibody library. We also produce control peptide-MHC complexes for counter screening during the antibody selection process.

Immunitrack has validated the application of its MHC/complexes for raising TCR-LAs in multiple systems including: phage and yeast display, humanized mouse and rabbit antibody libraries.




First-in-class TCR-LA characterization platform (AbScreen)

Immunitrack has implemented and validated a first-in-class TCR-LA characterization platform (AbScreen). TCR therapies have raised serious concerns about off-target toxicities that attacked healthy tissues. This highlights the urgency of pre-clinical testing to assess which peptides can be recognised by a TCR or TCR-LA.

To avoid cross-reactivity we have established a series of off-target assays:

- Alanine Scans in peptide/MHC complexes and in model cell lines
- Screening on peptide libraries which are unrelated to target peptide, but are validated epitopes in the corresponding MHC
- Positional scanning libraries screens on peptide libraries derived from the target.



Are you doing pre-clinical or clinical studies that require immunomonitoring?
Are you developing cancer or infectious diseases vaccines and need to identify specific T responses?

Contact us and learn how we can help you to:
 (I) define immunogenic epitopes (II) identify specific T cell responses

Tel. +45 2868 2159 · Immunitrack ApS · Lersø Parkallé 42 · 2100 Copenhagen Ø

Read more about the NeoScreen platform on our webpage:

<https://www.immunitrack.com/neoscreen-binding-assays/>